Initiate 50 mg cohort in Phase 2 dose exploration trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Jul 2023
- Due
- 30 Sep 2023
- Delivered
- Q3 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Q3 2023: Initiation of 50 mg cohort in Phase 2 dose exploration trial”
What we found
Evidence strength A What the grades mean
The company received FDA clearance in July 2023 to initiate the 50 mg cohort and subsequently completed enrollment and dosing of that cohort by November 2023, confirming initiation occurred within Q3 2023.
-
A Larimar Therapeutics, Inc. 10-Q filed 2023-11-14
“in July 2023, following the FDA’s review of our complete response, the FDA cleared initiation of a second cohort of our four-week, placebo-controlled, Phase 2 dose exploration trial of nomlabofusp in patients with FA to proceed to a 50 mg cohort” ✓ confirmed on the page
-
A Larimar Therapeutics, Inc. 10-Q filed 2023-11-14
“In November 2023, the Company completed enrollment and dosing of the 50 mg cohort of its Phase 2 double-blind dose exploration trial” ✓ confirmed on the page
Market reaction: the shares moved +27.0% against the S&P 500 over the three sessions around the disclosure (13 Nov 2023 to 16 Nov 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- 50 mg cohort in Phase 2 dose exploration trial
- Target
- 50 mg
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes: subject to partial clinical hold
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-LRMR-002967 · Corrections policy